Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Recommendation of “Buy” from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $43.00.

Several research analysts recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Morgan Stanley started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating on the stock. Finally, HC Wainwright began coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They issued a “buy” rating and a $42.00 target price for the company.

Bicara Therapeutics Stock Performance

BCAX opened at $19.12 on Thursday. The firm has a 50-day moving average price of $20.77. Bicara Therapeutics has a 1 year low of $16.01 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BCAX. First Turn Management LLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $14,324,000. The Manufacturers Life Insurance Company bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $582,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $57,913,000. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics during the third quarter worth approximately $809,000. Finally, Vestal Point Capital LP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $10,825,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.